Does Cigna Cover Vyvanse?

How Cigna Classifies Vyvanse on Its Formulary

Cigna places Vyvanse on Tier 3 (non-preferred brand) across most of its commercial Preferred Drug List (PDL) plans. Some Cigna Medicare Advantage and employer-sponsored plans push it to Tier 4. The tier assignment matters because it determines your copay or coinsurance percentage.

A Tier 3 classification means Cigna considers Vyvanse covered but not the first-line pharmacologic option for cost purposes. The insurer prefers that prescribers try lower-tier alternatives before authorizing brand Vyvanse. Under Cigna's 2025 commercial formulary, generic mixed amphetamine salts (the generic form of Adderall) and generic methylphenidate ER sit on Tier 1 or Tier 2, carrying copays between $5 and $25 [3]. Brand Vyvanse, by contrast, carries copays ranging from $50 to $150 depending on the specific employer plan design.

The arrival of generic lisdexamfetamine in August 2023 changed the picture for many Cigna members. Cigna's pharmacy benefit manager, Express Scripts (now Evernorth), added generic lisdexamfetamine capsules to several formularies at Tier 2 (preferred generic) or Tier 3 [4]. If your plan includes generic lisdexamfetamine at Tier 2, expect copays between $15 and $60 per 30-day supply. Capsule strengths from 10 mg through 70 mg are available in generic form.

Check your specific plan by logging into myCigna.com and searching "lisdexamfetamine" in the drug lookup tool. Formulary placement can differ between an employer's large-group plan and a Cigna individual marketplace plan purchased through Healthcare.gov.

Prior Authorization Requirements for Vyvanse Under Cigna

Most Cigna plans require prior authorization (PA) before covering Vyvanse or generic lisdexamfetamine. The PA process exists because lisdexamfetamine is a Schedule II controlled substance with abuse potential and carries a higher price point than first-line generics.

Cigna's clinical coverage policy for ADHD stimulants (policy 0535) generally requires documentation of an ADHD diagnosis meeting DSM-5 criteria, confirmation that the patient is aged 6 or older for ADHD use (or 18+ for binge eating disorder), and evidence that symptoms cause functional impairment in at least two settings such as work and home [5]. For step therapy requirements, Cigna typically asks for documentation that the patient tried and failed, or has a contraindication to, at least one preferred stimulant (generic amphetamine mixed salts or generic methylphenidate ER) within the past 12 months.

Your prescriber submits the PA request electronically or by fax. Cigna must respond within 72 hours for standard requests and 24 hours for urgent requests under most state regulations [6]. If the PA is denied, you receive a written explanation with appeal instructions.

A practical tip: ask your prescriber's office to include specific documentation of why alternatives failed. "Patient experienced insomnia and appetite suppression on mixed amphetamine salts 20 mg" is far more compelling to a Cigna reviewer than "patient prefers Vyvanse." The American Academy of Pediatrics ADHD guidelines recognize that medication response varies between individuals and that switching within or between stimulant classes is standard practice [7].

Brand Vyvanse vs. Generic Lisdexamfetamine: What Cigna Covers Differently

The FDA approved generic lisdexamfetamine capsules in 2023 after Takeda's patent exclusivity expired, and this shifted insurance economics significantly [8]. Cigna and its PBM Evernorth now have a lower-cost bioequivalent option.

Here is how coverage typically breaks down across Cigna plan types:

Cigna Commercial (Employer-Sponsored) Plans: Generic lisdexamfetamine is often placed on Tier 2 with copays of $15 to $60. Brand Vyvanse remains on Tier 3 or may be excluded entirely from some formularies with a "generic available" flag. If your plan has mandatory generic substitution, the pharmacy will automatically dispense the generic unless your prescriber writes "dispense as written" (DAW) and the PA supports brand-medically-necessary status.

Cigna Medicare Advantage (Part D) Plans: Coverage varies by region and plan. Many 2025 Part D formularies list generic lisdexamfetamine on Tier 3 with 25% to 33% coinsurance after the deductible [9]. Brand Vyvanse may require a Tier Exception request. Under the Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D (effective 2025), members hitting that threshold pay nothing for the remainder of the year [10].

Cigna Individual and Family Plans (ACA Marketplace): These plans must cover at least one drug per pharmacologic class. Lisdexamfetamine is covered, but the specific tier and PA requirements depend on the metal level (Bronze, Silver, Gold, Platinum) selected.

The price difference is substantial. Brand Vyvanse carries a wholesale acquisition cost (WAC) of approximately $380 to $420 for a 30-day supply [11]. Generic lisdexamfetamine WAC runs roughly $150 to $250, and negotiated rates between Cigna/Evernorth and generic manufacturers bring the cost lower.

Step Therapy: What Cigna Wants You to Try First

Step therapy is Cigna's requirement that patients try a less expensive medication before the insurer approves a costlier one. For ADHD stimulants, Cigna's step therapy protocol commonly follows a two-step sequence.

Step 1 requires a trial of a preferred generic stimulant. This usually means generic mixed amphetamine salts (immediate-release or extended-release) or generic methylphenidate ER (Concerta's authorized generic or other formulations). The trial period is typically 30 to 90 days. Step 2 permits Vyvanse or generic lisdexamfetamine if Step 1 medications proved ineffective, caused intolerable side effects, or are contraindicated.

There are clinical reasons why a prescriber might request a step therapy override. Lisdexamfetamine is a prodrug that requires enzymatic cleavage in the gut to release active d-amphetamine, which gives it a smoother pharmacokinetic profile and lower abuse potential compared to immediate-release amphetamine formulations [12]. A 2015 meta-analysis published in CNS Drugs (N=18 randomized controlled trials) found lisdexamfetamine produced statistically significant improvements in ADHD symptom scores with an effect size of 1.0 to 1.3 on the ADHD-RS-IV scale [13]. For patients with a history of substance use disorder or those who need consistent symptom control across 12 to 14 hours, lisdexamfetamine's pharmacology offers a measurable clinical advantage.

Your prescriber can request a step therapy exception by documenting medical necessity. Include records of adverse events from prior trials, relevant comorbidities (anxiety disorders, substance use history), and functional assessment scores.

How to Appeal a Cigna Denial for Vyvanse

If Cigna denies coverage for Vyvanse or generic lisdexamfetamine, you have the right to appeal. The process has defined timelines and escalation paths.

Internal Appeal (Level 1): File within 180 days of the denial. Cigna reviews the case with a physician who did not participate in the original denial. Include your prescriber's letter of medical necessity, clinical notes documenting prior medication trials, any relevant lab work or psychological testing, and copies of guideline recommendations supporting lisdexamfetamine. Cigna must issue a decision within 30 days for non-urgent requests and 72 hours for urgent cases [14].

External Review (Level 2): If the internal appeal fails, request an independent external review through your state's insurance department or through the federal external review process. An independent review organization (IRO) evaluates the case. The IRO's decision is binding on Cigna. Studies from the Government Accountability Office have found that external reviews overturn insurer denials in roughly 40% to 50% of cases [2].

Expedited Appeal: If your prescriber certifies that standard timelines would seriously jeopardize your health, Cigna must process the appeal within 72 hours for pre-service requests [6].

The strongest appeals pair clinical documentation with guideline citations. The American Academy of Child and Adolescent Psychiatry practice parameters and the National Institute for Health and Care Excellence (NICE) ADHD guidelines both recognize lisdexamfetamine as a recommended treatment option, and citing these can strengthen your case.

Out-of-Pocket Costs: What to Expect With and Without Cigna Coverage

Knowing the numbers helps you plan. These figures reflect 2025 averages for Cigna commercial plans.

With Cigna coverage (generic lisdexamfetamine, Tier 2): $15 to $60 per 30-day supply, depending on plan design and dosage. Some high-deductible health plans (HDHPs) require you to meet the full deductible first, meaning you pay the negotiated rate (often $80 to $180) until the deductible is satisfied.

With Cigna coverage (brand Vyvanse, Tier 3): $50 to $150 per 30-day supply after any applicable deductible. Coinsurance-based plans may charge 25% to 50% of the negotiated price.

Without insurance or if denied: The cash price for brand Vyvanse runs $350 to $450 at most retail pharmacies [11]. Generic lisdexamfetamine cash prices range from $200 to $350 but can drop to $30 to $80 with manufacturer discount programs or pharmacy discount cards.

Takeda's Vyvanse Savings Program: Commercially insured patients (not Medicare/Medicaid eligible) may qualify for Takeda's copay assistance card, which can reduce out-of-pocket costs to as low as $30 per fill for brand Vyvanse [15]. The program has annual caps, typically $60 to $100 saved per fill up to 12 fills per year.

Patient Assistance Programs: Uninsured patients with household incomes below 250% of the federal poverty level ($37,650 for a single individual in 2025) may qualify for Takeda's Help at Hand program, which provides Vyvanse at no cost [15].

For Cigna members using an HDHP paired with a Health Savings Account (HSA), Vyvanse and generic lisdexamfetamine are HSA-eligible expenses. You can pay your copay, coinsurance, or full pre-deductible cost with pre-tax HSA funds.

Vyvanse for Binge Eating Disorder: Different Cigna Coverage Rules

Vyvanse received FDA approval for moderate-to-severe binge eating disorder (BED) in adults in 2015, making it the first and, as of 2025, the only FDA-approved pharmacotherapy for this condition [1]. Cigna coverage for this indication follows a distinct pathway.

Cigna's clinical policy for BED typically requires a confirmed DSM-5 diagnosis of BED with moderate-to-severe severity (defined as 4 to 13+ binge episodes per week), documentation that the patient is aged 18 or older, and evidence of prior behavioral intervention or structured psychotherapy [16]. The prescriber must specify that the prescription is for BED, not ADHD, since the PA criteria differ.

A 2015 randomized controlled trial published in JAMA Psychiatry (N=724) found that lisdexamfetamine 50 mg and 70 mg daily reduced binge eating days per week from a baseline of 4.5 to 1.1 and 0.9 days, respectively, versus 2.3 days for placebo at 12 weeks (P<0.001) [17]. This trial (Study 344) formed the basis of the FDA's BED approval.

Some Cigna plans apply additional restrictions for BED coverage, including limiting approval to 12-month intervals before requiring re-authorization and capping the approved dose at 70 mg daily. Generic lisdexamfetamine carries the same FDA-approved indication for BED as brand Vyvanse, so the generic should be covered under the same clinical criteria.

Tips to Maximize Your Cigna Vyvanse Coverage

Getting the best coverage outcome often depends on preparation and knowing the system's rules.

Request your formulary in advance. Before your prescriber writes the prescription, check myCigna.com or call the number on your insurance card to confirm which tier lisdexamfetamine falls under on your specific plan. Ask whether prior authorization or step therapy applies.

Ask about quantity limits. Cigna commonly imposes a 30-day supply limit per fill for Schedule II medications. Some plans restrict early refills until day 25 to 28 of a 30-day cycle. If you travel frequently, ask about vacation supply overrides.

Use Cigna's preferred pharmacy network. Cigna/Evernorth offers lower copays at 90-day mail-order pharmacies (Express Scripts Pharmacy) compared to retail. For generic lisdexamfetamine, 90-day mail order may cost 2.0 to 2.5 times a single 30-day copay rather than 3 times, saving 15% to 30% annually.

Keep records of every medication trial. Document start dates, doses, duration, and specific adverse effects for each ADHD medication tried. This documentation is your evidence if you need to appeal.

Coordinate with your prescriber's office. Many large practices have staff dedicated to insurance authorizations. Ask the office to submit the PA proactively rather than waiting for a pharmacy rejection.

The American Medical Association's 2024 prior authorization survey found that 94% of physicians reported care delays due to PA requirements, with 33% reporting serious adverse events linked to PA delays [18]. Proactive documentation and submission cut your risk of treatment interruption.